Application of physiologically-based toxicokinetic modelling in oral-to-dermal extrapolation of threshold doses of cosmetic ingredients

Toxicology Letters

Volumn 227, Issue 3, 2014, Pages 189-202

  Gajewska, M ^a,d   Worth, A ^a   Urani, C ^d   Briesen, H ^b   Schramm, K W ^b,c  

^a JOINT RESEARCH CENTRE   (Italy)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c INSTITUTE OF EPIDEMIOLOGY   (Germany)

^d UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Caffeine; Coumarin; Hydroquinone; Physiologically based toxicokinetic (PBTK) modelling; Route to route extrapolation

Indexed keywords

CAFFEINE; COUMARIN; HYDROQUINONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BIOCHEMISTRY; CAUCASIAN; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIFFUSION COEFFICIENT; GASTROINTESTINAL ABSORPTION; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIVER METABOLISM; MALE; MONTE CARLO METHOD; NONHUMAN; NORMAL HUMAN; PARTITION COEFFICIENT; PHARMACOKINETICS; PHYSIOLOGICALLY BASED TOXICOKINETIC MODEL; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE PROPERTY RELATION; RAT; SKIN ABSORPTION; SKIN PENETRATION; TOXICOKINETICS;

CAFFEINE; COUMARIN; HYDROQUINONE; PHYSIOLOGICALLY BASED TOXICOKINETIC (PBTK) MODELLING; ROUTE-TO-ROUTE EXTRAPOLATION;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ALGORITHMS; ANIMALS; ANTIOXIDANTS; CAFFEINE; CALIBRATION; CENTRAL NERVOUS SYSTEM STIMULANTS; COSMETICS; COUMARINS; DATA INTERPRETATION, STATISTICAL; HUMANS; HYDROQUINONES; LIVER; MODELS, STATISTICAL; NO-OBSERVED-ADVERSE-EFFECT LEVEL; PHARMACOKINETICS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; SKIN; SKIN ABSORPTION; SPECIES SPECIFICITY;

EID: 84900496693     PISSN: 03784274     EISSN: 18793169     Source Type: Journal    
DOI: 10.1016/j.toxlet.2014.03.013     Document Type: Article

References (39)

1. Bessems J.G.M., Geraets L. Proper knowledge on toxicokinetics improves human hazard testing and subsequent health risk characterisation. A case study approach. Regul. Toxicol. Pharmacol. 2013, 67:325-334.
2. Bookout R.L., Quinn D.W., McDougal J.N. Parallel dermal subcompartments for modeling chemical absorption. SAR QSAR Environ. Res. 1997, 7:259-279.
3. Born S.L., Caudill D., Smith B.J., Lehman-McKeeman L.D. In vitro kinetics of coumarin 3,4-epoxidation: application to species differences in toxicity and carcinogenicity. Toxicol. Sci. 2000, 58:23-31.
4. Brent R.L., Christian M.S., Diener R.M. Evaluation of the reproductive and developmental risks of caffeine. Birth Defects Res. B: Dev. Reprod. Toxicol. 2011, 92:152-187.
5. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 1997, 13:407-484.
6. Brun R., Reichert P., Künsch H.R. Practical identifiability analysis of large environmental simulation models. Water Resour. Res. 2001, 37:1015-1030.
7. Chiu W.A., White P. Steady-state solutions to PBPK models and their applications to risk assessment I: Route-to-route extrapolation of volatile chemicals. Risk Anal. 2006, 26:769-780.
8. Corley R.A., English J.C., Hill T.S., Fiorica L.A., Morgott D.A. Development of a physiologically based pharmacokinetic model for hydroquinone. Toxicol. Appl. Pharmacol. 2000, 165:163-174.
9. Csajka C., Haller C.A., Benowitz N.L., Verotta D. Mechanistic pharmacokinetic modelling of ephedrine, norephedrine and caffeine in healthy subjects. Br. J. Clin. Pharmacol. 2005, 59:335-345.
10. EFSA Opinion of the scientific panel on food additives, flavourings, processing aids and materials in contacts with food (AFC) on a request from the commission related to coumarin. Question number EFSA-Q-2003-118. EFSA J. 2004, 104:1-36.
11. English J.C., Deisinger P.J. Metabolism and disposition of hydroquinone in Fischer 344 rats after oral or dermal administration. Food Chem. Toxicol. 2005, 43:483-493.
12. Ford R.A., Hawkins D.R., Mayo B.C., Api A.M. The in vivo dermal absorption and metabolism of [4-14C]coumarin by rats and by human volunteers under simulated conditions of use in fragrances. Food Chem. Toxicol. 2001, 39:153-162.
13. Ginsberg G., Hattis D., Russ A., Sonawane B. Physiologically based pharmacokinetic (PBPK) modeling of caffeine and theophylline in neonates and adults: Implications for assessing children's risks from environmental agents. J. Toxicol. Environ. Heal. A 2004, 67:297-329.
14. Hansen S., Henning A., Naegel A., Heisig M., Wittum G., Neumann D., Kostka K.H., Zbytovska J., Lehr C.M., Schaefer U.F. In-silico model of skin penetration based on experimentally determined input parameters. Part I: Experimental determination of partition and diffusion coefficients. Eur. J. Pharm. Biopharm. 2008, 68:352-367.
15. Kenyon E.M. Interspecies extrapolation. Methods Mol. Biol. 2012, 929:501-520.
16. Kletting P., Glatting G. Model selection for time-activity curves: the corrected Akaike information criterion and the F-test. Z. Med. Phys. 2009, 19:200-206.
17. Lelo A., Birkett D.J., Robson R.A., Miners J.O. Comparative pharmacokinetics of caffeine and its primary demethylated metabolites paraxanthine, theobromine and theophylline in man. Br. J. Clin. Pharmacol. 1986, 22:177-182.
18. Loizou G.D., Spendiff M. A human PBPK model for ethanol describing inhibition of gastric motility. J. Mol. Histol. 2004, 35:687-696.
19. McGregor D. Hydroquinone: an evaluation of the human risks from its carcinogenic and mutagenic properties. Crit. Rev. Toxicol. 2007, 37:887-914.
20. Mielke H., Abraham K., Götz M., Vieth B., Lampen A., Luch A., Gundert-Remy U. Physiologically based toxicokinetic modelling as a tool to assess target organ toxicity in route-to-route extrapolation - the case of coumarin. Toxicol. Lett. 2011, 202:100-110.
21. Moré J.J. The Levenberg-Marquardt algorithm: implementation and theory. Lect. Notes Math. 1978, 630:105-116.
22. Newton R., Broughton L.J., Lind M.J., Morrison P.J., Rogers H.J., Bradbrook I.D. Plasma and salivary pharmacokinetics of caffeine in man. Eur. J. Clin. Pharmacol. 1981, 21:45-52.
23. OECD SIDS Hydroquinone 1996.
24. OECD SIDS Caffeine: SIDS Initial assessment report for SIAM 14 2002.
25. Omlin M., Reichert P., Forster R. Biogeochemical model of Lake Zürich: model equations and results. Ecol. Modell. 2001, 141:77-103.
26. Otberg N., Patzelt A., Rasulev U., Hagemeister T., Linscheid M., Sinkgraven R., Sterry W., Lademann J. The role of hair follicles in the percutaneous absorption of caffeine. Br. J. Clin. Pharmacol. 2008, 65:488-492.
27. The European Parliament and the Council of the European Union REGULATION (EC) No 1223/2009 on cosmetic products. Off. J. Eur. Union 2009.
28. Poet T.S., Carlton B.D., Deyo J.A., Hinderliter P.M. Hydroquinone PBPK model refinement and application to dermal exposure. Food Chem. Toxicol. 2010, 48:3085-3092.
29. Reagan-Shaw S., Nihal M., Ahmad N. Dose translation from animal to human studies revisited. FASEB J. 2008, 22:659-661.
30. Rietjens I.M.C.M., Boersma M.G., Zaleska M., Punt A. Differences in simulated liver concentrations of toxic coumarin metabolites in rats and different human populations evaluated through physiologically based biokinetic (PBBK) modeling. Toxicol. Vitr. 2008, 22:1890-1901.
31. Ritschel W.A., Brady M.E., Tan H.S.I. First-pass effect of coumarin in man. Int. J. Clin. Pharmacol. Ther. Toxicol. 1979, 17:99-103.
32. Ritschel W.A., Brady M.E., Tan H.S.I., Hoffmann K.A., Yiu I.M., Grummich K.W. Pharmacokinetics of coumarin and its 7-hydroxy-metabolites upon intravenous and peroral administration of coumarin in man. Eur. J. Clin. Pharmacol. 1977, 12:457-461.
33. Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol. Vitr. 2008, 22:457-467.
34. Soetaert K. R package FME: inverse modelling, sensitivity, Monte Carlo - applied to a dynamic simulation model 2010.
35. Soetaert K., Petzoldt T. Inverse modelling, sensitivity and Monte Carlo analysis in R using package FME. J. Stat. Softw. 2010, 33:1-28.
36. Thorn C.F., Aklillu E., McDonagh E.M., Klein T.E., Altman R.B. PharmGKB summary: Caffeine pathway. Pharmacogenet. Genomics 2012, 22:389-395.
37. Tibaldi R., Ten Berge W., Drolet D. IH SkinPerm Help Manual 2011.
38. Wester R.C., Melendres J., Hui X., Cox R., Serranzana S., Zhai H., Quan D., Maibach H.I. Human in vivo and in vitro hydroquinone topical bioavailability, metabolism, and disposition. J. Toxicol. Environ. Heal. A 1998, 54:301-317.
39. Zandvliet A.S., Huitema A.D.R., De Jonge M.E., Den Hoed R., Sparidans R.W., Hendriks V.M., Van Den Brink W., Van Ree J.M., Beijnen J.H. Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine. Basic Clin. Pharmacol. Toxicol. 2005, 96:71-79.